BioArctic is a Swedish biopharma company with the vision to become a world-leader in the research and development of disease-modifying treatments for patients with neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease, and pioneering treatment methods for complete spinal cord injuries. Gunilla Osswald, CEO, explains how BioArctic is uniquely positioned to achieve this vision thanks to its innovative project portfolio, high scientific competence, strategic partnerships with Eisai and AbbVie, collaboration with leading academic research groups, and strong financial position.
Our broad innovative portfolio spanning from early discovery to Phase III, strong collaborations with strategic partners and universities combined with our solid financial situation make us a unique biopharma company, not only in Sweden but globally
